Metribolone

Metribolone (developmental code R1881, also known as methyltrienolone) is a synthetic and orally active anabolic–androgenic steroid (AAS) and a 17α-alkylated nandrolone (19-nortestosterone) derivative which was never marketed for medical use but has been widely used in scientific research as a hot ligand in androgen receptor (AR) ligand binding assays (LBAs) and as a photoaffinity label for the AR.^[1][2][3] More precisely, metribolone is the 17α-methylated derivative of trenbolone. It was investigated briefly for the treatment of advanced breast cancer in women in the late 1960s and early 1970s, but was found to produce signs of severe hepatotoxicity at very low dosages, and its development was subsequently discontinued.^[2][4]

Metribolone

Clinical data
Other names	Methyltrienolone, 17α-Methyltrenbolone; R1881; R-1881; RU-1881; NSC-92858; 17α-Methyl-19-nor-Δ9,11-testosterone; 17α-Methylestra-4,9,11-trien-17β-ol-3-one
Routes of administration	By mouth
Drug class	Androgen; Anabolic steroid; Progestogen
Identifiers
IUPAC name (8S,13S,14S,17S)-17-Hydroxy-13,17-dimethyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
CAS Number	965-93-5 Y
PubChem CID	261000
IUPHAR/BPS	2857
ChemSpider	229099 Y
UNII	2C323EGI97
KEGG	C14257 Y
ChEBI	CHEBI:379896 Y
ChEMBL	ChEMBL166444 Y
CompTox Dashboard (EPA)	DTXSID8034162
ECHA InfoCard	100.190.113
Chemical and physical data
Formula	C19H24O2
Molar mass	284.399 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@]1(CC[C@@H]2[C@@]1(C=CC3=C4CCC(=O)C=C4CC[C@@H]23)C)O
InChI InChI=1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1 N Key:CCCIJQPRIXGQOE-XWSJACJDSA-N N
(verify)

Medical uses

Metribolone was never approved for medical use,^[2] a situation unlikely to change given its liver toxicity even at low doses.^[2] It was studied for the potential treatment of advanced breast cancer in women but development was abandoned.^[2][4]

Side effects

See also: Anabolic steroid § Adverse effects

Side effects of metribolone include virilization and hepatotoxicity among others.^[2]

Pharmacology

Pharmacodynamics

Metribolone is an AAS, or an agonist of the AR, with both anabolic and androgenic activity.^[2] It is one of the most potent AAS to have ever been synthesized, with 120 to 300 times the oral anabolic potency and 60 to 70 times the androgenic potency of the reference AAS methyltestosterone in castrated male rats, although the same level of potency has not been observed in studies in humans.^[2][4] In addition to the AR, metribolone has high affinity for the progesterone receptor (PR), and binds to the glucocorticoid receptor (GR) as well.^[5][6] The drug was also identified in 2007 as a potent antimineralocorticoid, with similar affinity for the mineralocorticoid receptor as aldosterone and spironolactone.^[7] In addition, metribolone was identified in 2010 as a potent inhibitor of 3β-hydroxysteroid dehydrogenase (3β-HSD) 1 and 2 (IC₅₀ = 0.02 and 0.16 μM, respectively).^[8] On the basis of this finding, it has been said that metribolone should be used very cautiously in scientific research, taking into account 3β-HSD inhibition to avoid erroneous interpretation.^[8]

Metribolone has a high potential for hepatotoxicity, similarly to other 17α-alkylated AAS.^[9] However, the hepatotoxic potential of metribolone appears to be exceptionally high, likely in relation to its very high potency and metabolic stability; in a study of treatment with the drug for advanced breast cancer, severe hepatic dysfunction was observed at very low dosages.^[4]

Relative affinities (%) of metribolone and related steroids

Compound	Chemical name	PRTooltip Progesterone receptor	ARTooltip Androgen receptor	ERTooltip Estrogen receptor	GRTooltip Glucocorticoid receptor	MRTooltip Mineralocorticoid receptor
Testosterone	T	1.0	100	<0.1	0.17	0.9
Nandrolone	19-NT	20	154	<0.1	0.5	1.6
Trenbolone	∆9,11-19-NT	74	197	<0.1	2.9	1.33
Trestolone	7α-Me-19-NT	50–75	100–125	?	<1	?
Normethandrone	17α-Me-19-NT	100	146	<0.1	1.5	0.6
Metribolone	∆9,11-17α-Me-19-NT	208	204	<0.1	26	18
Mibolerone	7α,17α-DiMe-19-NT	214	108	<0.1	1.4	2.1
Dimethyltrienolone	∆9,11-7α,17α-DiMe-19-NT	306	180	0.1	22	52
Notes: Values are percentages (%). Reference ligands (100%) were progesterone for the PRTooltip progesterone receptor, testosterone for the ARTooltip androgen receptor, estradiol for the ERTooltip estrogen receptor, DEXATooltip dexamethasone for the GRTooltip glucocorticoid receptor, and aldosterone for the MRTooltip mineralocorticoid receptor. Sources: [10][11]

• v
• t
• e

Relative affinities of nandrolone and related steroids at the androgen receptor

Compound	rAR (%)	hAR (%)
Testosterone	38	38
5α-Dihydrotestosterone	77	100
Nandrolone	75	92
5α-Dihydronandrolone	35	50
Ethylestrenol	ND	2
Norethandrolone	ND	22
5α-Dihydronorethandrolone	ND	14
Metribolone	100	110
Sources: See template.

Pharmacokinetics

Metribolone has very low affinity for human serum sex hormone-binding globulin (SHBG), less than 5% of that of testosterone and less than 1% of that of dihydrotestosterone (DHT).^[12]

Chemistry

See also: List of androgens/anabolic steroids

Metribolone, also known as 17α-methyltrenbolone, as well as 17α-methyl-δ^9,11-19-nortestosterone or 17α-methylestra-4,9,11-trien-17β-ol-3-one, is a synthetic estrane steroid and a 17α-alkylated derivative of nandrolone (19-nortestosterone).^[1][2] It is the C17α methylated derivative of trenbolone (δ^9,11-19-nortestosterone) and the C9- and C11-dehydrogenated (δ^9,11) analogue of normethandrone (17α-methyl-19-nortestosterone).^[1][2] Other close relatives and derivatives of metribolone include mibolerone (7α,17α-dimethyl-19-nortestosterone) and dimethyltrienolone (RU-2420; 7α,17α-dimethyl-δ^9,11-19-nortestosterone).^[1][2] In addition to AAS, trimethyltrienolone (R2956; 2α,2β,17α-trimethyl-δ^9,11-19-nortestosterone), a highly potent antiandrogen, has been derived from metribolone.^[13][14]

History

Metribolone was first described in the literature in 1965.^[2] It was studied clinically in the late 1960s and early 1970s, most notably in the treatment of advanced breast cancer.^[2] The drug was found to be effective and showed weak androgenicity, but also produced severe signs of hepatotoxicity, and was ultimately never marketed.^[2][4] By the mid-1970s, metribolone was becoming an accepted standard as a ligand and agonist of the AR in scientific research.^[2] It remains in wide use for this purpose today.^[2] Aside from scientific research, metribolone has also been encountered as an AAS in non-medical contexts, for instance in doping in sports and bodybuilding.^[2]

Society and culture

Generic names

Metribolone is the generic name of metribolone and its INNTooltip International Nonproprietary Name.^[1] It is also known by the name methyltrienolone and its developmental code names R1881, R-1881, RU-1881, and RU1881, and is very commonly referred to by these other names rather than as metribolone in the scientific literature.^[1]

Doping in sports

Prior to the 2008 Beijing Olympic Games, 11 members of the Greek national weightlifting team and 4 Greek track and field athletes tested positive for metribolone.^[15]

References

1. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 654–. ISBN 978-1-4757-2085-3.
2. William Llewellyn's Anabolics. Molecular Nutrition LLC. 2011. pp. 546–. ISBN 978-0-9828280-1-4.
3. Brinkmann AO, Kuiper GG, de Boer W, Mulder E, Bolt J, van Steenbrugge GJ, van der Molen HJ (January 1986). "Characterization of androgen receptors after photoaffinity labelling with [3H]methyltrienolone (R1881)". Journal of Steroid Biochemistry. 24 (1): 245–249. doi:10.1016/0022-4731(86)90058-0. PMID 2422446.
4. Brueggemeier RW (2006). "Sex Hormones (Male): Analogs and Antagonists". In Meyers RA (ed.). Encyclopedia of Molecular Cell Biology and Molecular Medicine. Vol. 13 (2nd ed.). doi:10.1002/3527600906.mcb.200500066. ISBN 3527600906.
5. Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Current Medicinal Chemistry. 7 (2): 211–247. doi:10.2174/0929867003375371. PMID 10637363.
6. Ho-Kim MA, Tremblay RR, Dubé JY (November 1981). "Binding of methyltrienolone to glucocorticoid receptors in rat muscle cytosol". Endocrinology. 109 (5): 1418–1423. doi:10.1210/endo-109-5-1418. PMID 6975208.
7. Takeda AN, Pinon GM, Bens M, Fagart J, Rafestin-Oblin ME, Vandewalle A (February 2007). "The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor". Molecular Pharmacology. 71 (2): 473–482. doi:10.1124/mol.106.031112. PMID 17105867. S2CID 28647372.
8. Zheng F (2010). "Methyltrienolone (R1881) is a Potent Inhibitor of 3B-Hydroxysteroid Dehydrogenase (3B-HSD) Activity". Characterization of Enzymes Involved in the Metabolism of Dihydrotestosterone, the Most Potent Natural Androgen (thesis). pp. 91–103. CiteSeerX 10.1.1.428.3729.
9. Krüskemper HL, Noell G (July 1966). "Liver toxicity of a new anabolic agent: methyltrienolone (17-alpha-methyl-4,9,11-estratriene-17 beta-ol-3-one)". Steroids. 8 (1): 13–24. doi:10.1016/0039-128x(66)90114-0. PMID 5955468.
10. Delettré J, Mornon JP, Lepicard G, Ojasoo T, Raynaud JP (January 1980). "Steroid flexibility and receptor specificity". Journal of Steroid Biochemistry. 13 (1): 45–59. doi:10.1016/0022-4731(80)90112-0. PMID 7382482.
11. Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP (1987). "Towards the mapping of the progesterone and androgen receptors". Journal of Steroid Biochemistry. 27 (1–3): 255–269. doi:10.1016/0022-4731(87)90317-7. PMID 3695484.
12. Saartok T, Dahlberg E, Gustafsson JA (June 1984). "Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin". Endocrinology. 114 (6): 2100–2106. doi:10.1210/endo-114-6-2100. PMID 6539197.
13. Phillipps GH (22 October 2013). "Structure-Activity Relationships in Steroid Anaesthetics". In James VJ, Pasqualini JR (eds.). Proceedings of the Fourth International Congress on Hormonal Steroids: Mexico City, September 1974. Elsevier Science. p. 618. ISBN 978-1-4831-4566-2. R-2956 [41-43], a dimethyl derivative of an extremely potent androgen, R 1881 [44], is a powerful testosterone antagonist with very low androgenic activity.
14. Harms AF (1 January 1986). Innovative Approaches in Drug Research: Proceedings of the Third Noordwijkerhout Symposium on Medicinal Chemistry, Held in the Netherlands, September 3-6, 1985. Elsevier. ISBN 978-0-444-42606-2. At this stage, RU 2956 exerts a competitive effect about 4 times less marked than metribolone may be because the steric hindrance of the dimethyl group in position C-2 interferes with H-bond formation between the C-3 oxygen and the receptor protein, i.e., with the recognition step, and consequently, with the association rate.
15. "Eleven Greek weightlifters test positive; coach suspended". Associated Press / USATODAY.com. 2008-04-04. Retrieved 2009-06-28.

External links

• Metribolone at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• Methyltrienolone - William Llewellyn's Anabolic.org Archived 2016-04-07 at the Wayback Machine